|8653305||Compound having S1P receptor binding potency and use thereof|
Provided are: a compound represented by formula (I): (wherein ring A and ring D each represent a cyclic group which may have a substituent(s); E and G each represent a bond or a spacer having 1 to 8...
|8569545||Process for the preparation of enantiomerically pure amines|
The present invention relates to an improved process for the preparation of (R)-1-aminoindan (2), rasagiline (1) and pharmaceutically acceptable salts of rasagiline. ...
|8334409||Process for purifying rasagiline base|
Disclosed is crystalline R(+)-N-propargyl-1-aminoindan and racemic N-propargyl-1-aminoindan characterized by colorless crystals a pharmaceutical composition comprising the same, and the process for the manufacture and the validation thereof. Also disclosed is pure l...
|8283495||Process for preparing optically active cyclic amines|
Optically active cyclic amines of the formula (I) or salts thereof in which A, R0, R are each as defined in claim 1, and R0 and A, or R and A, or R0 and R may also form rings,
|8084647||Two-photon probe for real-time monitoring of intracellular calcium ions, method for preparing the probe and method for real-time monitoring of intracellular calcium ions using the probe|
A two-photon probe for real-time monitoring of intracellular calcium ions is provided. The two-photon probe is very suitable for real-time imaging of intracellular calcium ions, shows 20˜50-fold TPEF enhancement in response to Ca2+, has a dissociation co...
|8039674||Compound having S1P receptor binding potency and use thereof|
Provided are: a compound represented by formula (I): (wherein ring A and ring D each represent a cyclic group which may have a substituent(s); E and G each represent a bond or a spacer having 1 to 8 atoms in its main chain;...
|7838703||Diaromatic amine derivatives as antioxidants|
A diaromatic amine compound having the general formula: wherein R1 and R2 together with the carbon atoms to which they are bonded are joined together to form a C3-C30 ring, and R
|7649115||MAO-B inhibitors useful for treating obesity|
The invention provides novel compounds of formulae I and II: that are monoamine oxidase-B inhibitors, which can be useful in treating obesity, diabetes, and/or cardiometabolic disorders (e.g., hypertension, dyslipidemias, h...
|7368448||2-(arylalkoxy)-1-phenylethylamine derivatives as NKantagonist and serotonin reuptake inhibitors|
Compounds of the following formula (I) wherein R1 R2, n, Ar1 and A2 are as defined in the specification, in vivo-hydrolysable precursors thereof, pharmaceutically acceptable salts thereof, the use in therapy and pharmaceut...
|7365231||Compound with antitumor activity and preparation method therefor|
The present invention provides the diaminophenyladamantane derivatives with antitumor activities and the preparation method therefore. The method includes a step of reacting an aromatic diol with at least one 5-halo-2-nitrophenol in the presence of at least one inor...
|7319171||Sertraline hydrochloride form II and methods for the preparation thereof|
The present invention is directed to Form II of sertraline hydrochloride and novel methods for its preparation. According to the present invention, sertraline hydrochloride Form II may be produced directly form sertraline base or sertraline mandelate. It may also be...
|7309497||Injectable pharmaceutical composition for systematic administration of pharmacologically active ingredients|
The invention relates to novel pharmaceutical compositions for the systemic administration of pharmacologically active ingredients. The invention relates in particular to an injectable pharmaceutical composition comprising (a) a pharmacologically active ingredient i...
|7264890||Electroluminescent material, electroluminescent element and color conversion filter|
An electroluminescent element is disclosed, comprising an electroluminescent material and a fluorescent substance emitting light having an emission maximum at the wavelength different from that of light emitted from the electroluminescent material upon absorption of...
|7262327||Recycling process for preparing sertraline|
Provided is a recycling process for preparing sertraline, which may be carried out on an industrial scale. ...
|7259271||Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation|
Compounds of formula I: where R1, R2 and R3 are the same or different and signify hydrogens, halogens, alkyl, alkylaryl, alkyloxy, hydroxy, nitro, amino, alkylcarbonylamino, alkyl...
|7252894||Anthracene compound for organic electroluminescent device|
An anthracene compound for an organic electroluminescent device, having formula (I) or (II) wherein R1, R2, R3, R4, R5, and R6 ...
|7189876||Methods for preparing sertraline hydrochloride polymorphs|
This invention relates to crystalline polymorphs of sertraline hydrocloride, i.e. (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphtalenamine hydrochloride, denominated form I, II and V, and methods for their preparation. ...
An acid salt of sertraline, wherein the acid is citric acid, fumaric acid, malic acid, maleic acid, malonic acid, phosphoric acid, succinic acid, sulfuric acid, L-tartaric acid, HBr, acetic acid, benzoic acid, benzenesulfonic acid, ethanesulfonic acid, lactic acid, ...
|7173153||Sertraline hydrochloride form II and methods for the preparation thereof|
This invention relates to a method for the preparation of sertraline hydrochloride, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphtalenamine hydrochloride, in its crystalline form II. ...
|7049337||Derivatives of 2-aminotetralins and pharmaceutical analogs thereof exhibiting differential CNS receptor activity and behavior|
Aminotetralin derivatives and pharmacological analogs thereof which contain an N-propynyl group exhibit differential dopaminergenic receptor activity. The subject compounds are useful in affecting dopamine receptor activity, particularly in exhibiting differing acti...
|7041703||2-aminotetralines and pharmaceutical compositions for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies|
2-Aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory pathologies (particularly septic shock) and/or autoimmune pathologies in which the aetiopathogenic role of inflammatory ...
|7026498||Ligands for metals and improved metal-catalyzed processes based thereon|
One aspect of the present invention relates to novel ligands for transition metals. A second aspect of the present invention relates to the use of catalysts comprising these ligands in transition metal-catalyzed carbon-heteroatom and carbon-carbon bond-forming react...
|6949575||Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives|
The present invention provides compounds of Formula (I) and a method of treating Alzheimer's disease using a compound of Formula (I), wherein: R1 and R2 include alkyl and phenylalkyl; R3 is hydrogen or alkyl; and R4 and R
(−)-3-[3-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-yloxy]-4-methoxyanilino]-2-methyl-2-cyclopenten-1-one, or its hydrate or solvate, or a pharmaceutical composition containing the same. ...
|6939992||Polymorphic forms of sertraline hydrochloride|
A crystalline form of sertraline hydrochloride was found, referred to hereinafter as polymorphic form CSC2 having a dissolution rate which surprisingly will increase rate of absorption of a drug. Furthermore, different crystalline forms of sertraline hydrochl...
|6933410||Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine|
A process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine and acid addition salts thereof from 2-aminoindan. The process comprises protecting the amino group of 2-aminoindan, acetylating the ring in the protected compound, reducing the acetyl group to ethyl t...
|6933411||Aromatic diamine and polyimide thereof|
The aromatic diamine compound of the present invention is represented by the following formula (1), and from the aromatic diamine compound a polyimide having a repeating unit represented by the following formula (4), which has low-temperature adherability, can be ob...
|6897340||Processes for preparation of polymorphic form II of sertraline hydrochloride|
Provided are processes for preparation of crystalline sertraline hydrochloride Form II substantilly free of other polymorphic forms of sertraline hydrochloride, preferably on an industrial scale. ...
Aminomethyl-phenyl-cyclohexanone derivatives of formula I or Ia, their diastereomers, enantiomers and salts formed with a physiologically tolerated acid. Also disclosed are processes for preparing the same, pharmaceuti...
|6870070||Process to prepare 2-aminoindan derivatives|
The present invention relates to (2S)-enantiomers of 2-aminoindan derivatives of formula I: and a novel process for the preparation of them. ...
|6858652||Sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them|
The present invention is directed to novel polymorphic Forms XI, XII, XIII, XIV, XV and XVI of sertraline hydrochloride, to processes for preparing them, methods of using them to treat disease, methods of using them to make other sertraline hydrochloride forms, and ...
|6849345||Organic electroluminescent devices with high luminance|
Disclosed is a multilayer electroluminescent device comprising a cathode, an anode, a light emitting layer (LEL) and a layer disposed between the cathode and anode containing a naphthalene compound represented by formula (1):
|6844368||Compounds useful in pain management|
The present invention relates to novel oxo-aminotetralin compounds of the formula (I) wherein X, R1, R2, R3, R4, R5, and R6 are defined herein. ...
|6809221||Process for preparing (+)-cis-sertraline|
The present invention is directed to (+)-cis-sertraline hydrochloride and methods of preparation. The present invention also includes processes for making sertraline having a cis/trans ratio greater than 3:1, greater than or equal to 8:1, or between about 8:1 and ab...
|6784210||Compound and a novel process for their preparation|
The present invention is directed to a procedure for making an enantiomerically enriched compound containing a hydronaphthalene ring structure. The process involves reacting oxabenzonorbornadienes with nucleophiles using rhodium as a catalyst and in the presence of ...
|6753128||Photoresist additive for preventing acid migration and photoresist composition comprising the same|
Photoresist additives for preventing the acid generated in the exposed area during the course of a photolithography process from being diffused to the unexposed area, photoresist compositions containing the same, and a process for forming a photoresist pattern using...
|6747149||Glucamine salts for treating hepatitis virus infections|
N-Substituted glucamine compounds of formula I are effective in treatment of hepatitis infections, including hepatitis B and hepatitis C. In treating hepatitis infections the compounds of formular I may be used alone, or in combinatioin with another antiviral agent ...
|6723455||Organic electro-luminescent element and material of organic electro-luminescent element|
An electro-luminescent element comprising an organic compound layer is disclosed. The organic compound layer contains a compound represented by Formula I or Formula V: wherein R1 and R2 are each a s...
|6710089||Substituted N-fused-phenyl-N-benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity|
The invention relates to substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atheroscle...
|6696608||Transfer hydrogenation process|
A catalytic transfer hydrogenation process is provided. The process can be employed to transfer hydrogenate N-substituted imines and iminium salts, which are preferably prochiral. The catalyst employed in the process is preferably a metal complex with one...